HSCT Shows Benefits in Some People With Secondary Progressive MS in Small Study
February 11, 2020
February 11, 2020
NEW YORK, Feb. 11 -- The National Multiple Sclerosis Society issued the following news:
Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs of clinical or MRI inflammatory activity in the year prior to the procedure. Five years after the procedure, 42% of participants were stable with no further progression of disabilit . . .
Researchers from Florence, Italy report on a small, open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT (Hematopoietic Stem Cell Transplantation). Most showed signs of clinical or MRI inflammatory activity in the year prior to the procedure. Five years after the procedure, 42% of participants were stable with no further progression of disabilit . . .